News Source: Honolulu Advertiser
| about 1 month ago
Benlysta, a new drug designed specifically to treat systemic lupus erythematosus, has passed a second clinical trial, paving the way for it to become the first new treatment approved for lupus in 50 years. Its maker, Human Genome Sciences of...
News Source: International Business Times
| about 1 month ago
Human Genome Sciences Inc said its experimental lupus drug Benlysta eased symptoms in more than 43 percent of patients who took it in a clinical trial, paving the way for approval of the first new treatment for the disease in 50 years. The news sent...
News Source: National Public Radio
| about 1 month ago
A second late-stage clinical test of Human Genome Sciences' Benlysta , which suppresses antibody-producing cells in the immune system, showed good results, buoying hopes for a fresh lupus treatment. The experimental drug's roots stretch back to the...
News Source: Washington Post
| about 1 month ago
If approved, Benlysta could be available on the market late next year. Many industry analysts and Lupus experts wondered if a new medication for treating the disease would ever come; it has been over 50 years since a drug was approved for use against...
News Source: Fox News
| about 1 month ago
Stock futures were pointing toward a positive opening after Ford posted a surprise profit for the third quarter. Shares were up 32.7% in pre-market trading after the company announced its experimental lupus drug Benlysta was showed successful results...
News Source: Fox News
| about 1 month ago
Drug stocks advanced in early trading Monday as shares of Human Genome Sciences leaped on the release of more positive Phase III clinical data for its new lupus drug Benlysta...Arca Biotechnology Index , meanwhile, jumped 3.7% to 852.14, propelled by...